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Introduction
Mold is ubiquitous in our environment and is a
common allergen in allergic diseases.1–5 There are 2
major approaches in allergen tests: the skin test (in
vivo) and serum assays for allergen-specific
immunoglobulin E (IgE) antibodies (in vitro). In
vitro tests have traditionally been considered less
sensitive than skin tests for investigation of mold
allergy.6–10 This has been attributed to technical
problems such as difficulty in binding the mold
antigen to the carrier substrate. The Pharmacia
ImmunoCAP system (CAP) is a second-generation
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in vitro test using a 3-dimensional cellulose solid
allergen phase. Some studies reported that CAP had
diagnostic performance similar to that of the skin
test.11–15 Our previous study found CAP achieved
sensitivity similar to that of the skin test in detecting
allergy to house dust, but the positive rates of CAP
were significantly lower than those of the skin test
when diagnosing allergy to pollen, dog dander, and
Candida.10 Only a few studies have reported on the
performance of CAP in the evaluation of mold
allergy.9–12 The purpose of this study was to compare
the performance of the skin test and CAP in the
evaluation of mold allergy.
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Methods
This study was undertaken after approval by the
Institutional Review Board of Taichung Veterans
General Hospital, Taiwan, R.O.C. From September
2003 to February 2004, patients with allergic rhinitis
were enrolled from the ENT outpatient clinic in
Taichung Veterans General Hospital. The diagnosis
of allergic rhinitis was based on the clinical criteria
gold standard: typical clinical history and apparent
symptoms of sneezing, rhinorrhea, nasal itching,
and/or nasal obstruction for more than 2 years.15
Patients who had taken any antihistamine within 1
week or astemizole within 3 months were excluded.16,17
Patient evaluation included serum CAP test
(Pharmacia, Uppsala, Sweden) and intradermal skin
test (Tori Ltd, Tokyo, Japan). The skin test included
house dust, cotton, ragweed, and the 5 fungal
allergens (Candida,  Alternaria,  Aspergillus,
Cladosporium, and Penicillium). The volar surface
of the forearm was used for intradermal testing.
About 0.02 mL of each extract alone with control
solutions (histamine for positive control and normal
saline for negative control) were intradermally
injected; the size of wheal was 4 mm in diameter.
The skin reaction was read 15–20 minutes after the
injection. If the wheal diameter was more than
9 mm or the diameter of erythema was more than
20 mm, the reaction was considered positive. The IgE
antibodies to these 5 fungal allergens were measured
with CAP and regarded as positive if the values were
* 0.35 kU/L. The results were analyzed by the
McNemar test.
Results
A total of 75 patients (44 males and 31 females)
were enrolled in this study. Their ages ranged from
12 to 76 years old, with a mean age of 31.9 years.
Sixty-eight patients (90.6%) had positive skin test
results. Fifty-five patients (73.3%) had positive skin
reactions to fungal allergens. The positive rates of
the skin test and CAP were 56.0% versus 9.3% for
Candida, 22.7% versus 1.3% for Alternaria, 16%
versus 9.3% for Aspergillus, 14.7% versus 1.3% for
Cladosporium, and 32% versus 8% for Penicillium
(Table 1). The results were compared using the
McNemar test and showed statistically significant
differences in the positive rate of the 2 testing methods
in Candida,  Alternaria,  Cladosporium,  and
Penicillium (p = 0.000, 0.000, 0.006, and 0.001,
respectively).
Discussion
Detection of allergens and allergen avoidance are
crucial in the treatment of allergic diseases. The skin
test (in vivo) and serum assay for specific IgE antibodies
(in vitro) are currently the 2 general approaches in
wide use. Both have their own advantages and
disadvantages. The skin test is more sensitive but is
uncomfortable and time consuming. The skin reactions
can be influenced by certain medications and
dermatologic conditions.15–17 The in vitro test is less
sensitive, but medications or skin conditions will not
influence results. Thus, the in vitro tests are more
specific.
A number of different in vitro methods have been
devised. CAP is a clear advance in in vitro testing
because of its unique solid phase and antibody
system.11–16 Some studies have reported the
performance of CAP to be similar to that of the skin
test.11–15 But the sensitivity of CAP can vary between
different inhalant allergens.10,14 A study performed by
the senior author (R.S.J.) found CAP achieved
sensitivity similar to that of the skin test (Tori Ltd) in
detecting dust allergy. However, the positive rates
were significantly lower than those of the skin test in
detecting pollen, dog dander, and Candida.10
The identification of mold allergens is problematic.
The clinical history is rarely conclusive for mold allergy,
since seasonal variation may coincide with variations in
pollen and mite allergens. Currently, up to 80,000
Table 1. The results of the skin test and CAP test
Skin test + Skin test –
Candida
CAP + 7 0
CAP – 35 33
Alternaria
CAP + 1 0
CAP – 16 58
Aspergillus
CAP + 2 5
CAP – 10 58
Cladosporium
CAP + 0 1
CAP – 11 63
Penicillium
CAP + 2 4
CAP – 22 47
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species of fungi have been described. They are also
known to mutate frequently; therefore, an
extraordinarily large number of variants exist. The
fungal antigens have more complex macromolecular
composition than other allergen sources. The
characterization, purification, and standardization of
allergens from such a wide range of fungal species are
very difficult.18–22 Many commercial allergen extracts
show variable potency.21–23 Also, the coupling of the
allergen extract to the insoluble solid phase of the in
vitro test is limited because of the complex composition.
It is traditionally thought that the in vitro tests are less
sensitive in the evaluation of mold allergy than the skin
test.6–10 In our results, the positive rate of the skin test
was higher than that of CAP. There were significantly
different positive rates between the 2 testing methods
among 4 of 5 fungi.
Another possible reason for the discrepancy
between the results of the skin and in vitro tests is the
use of different allergens in the 2 tests.6,18 There are
subtle differences in antigens used in the skin test and
CAP: Alternaria kikuchiana versus Alternaria tenuis,
Cladosporium cladosporioides versus Cladosporium
herbarum, and Penicillium luteum versus Penicillium
notatum. Different species in the same genera could
have allergenic differences.24–27 To the best of our
knowledge, there are no reports about the degree of
cross-reactivity between these 3 different pairs of
mold allergens. Because a huge number of variant
strains exist, the selected allergen of commercially
available extracts for the skin test could be different
from the allergen of the in vitro test. Different strains
could have different allergenic properties, and result
in different positive rates. We found similar situations
in previous studies comparing skin tests and in vitro
tests.6,28
Neither the in vivo nor the in vitro approach
provides an ideal solution. The results of allergy tests
should be interpreted in conjunction with clinical
history and physical findings. Optimal use of allergy
tests requires a high level of knowledge regarding
allergen composition, distribution, local importance,
and selection of adequate test method. Furthermore,
it is important to point out that all methods have both
advantages and disadvantages.
The diagnosis of mold allergy is based on clinical
history and the evidence of IgE-mediated sensitization
to mold. Since the clinical history is rarely conclusive
for mold allergy, an allergy test mainly determines the
diagnosis of mold allergy. Our results showed that the
positive rate of the skin test was significantly higher
than that of CAP in detecting mold allergy. King29 has
suggested that the skin test, with its higher sensitivity,
could be used as the primary screening test and CAP,
with its higher specificity, could be a confirmatory test.
In conclusion, the skin test and CAP are 2 major
approaches for detecting allergens. Our results showed
the positive rate of the skin test was higher than that of
CAP in the evaluation of mold allergy. Clinicians
should note that a discrepancy may exist between the
results of in vitro and in vivo tests when evaluating
mold allergy.
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